Acer Therapeutics Stock Price, News & Analysis (NASDAQ:ACER)

$17.28 -0.88 (-4.85 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$17.28
Today's Range$17.28 - $18.15
52-Week Range$5.69 - $22.63
Volume23,188 shs
Average Volume21,407 shs
Market Capitalization$133.77 million
P/E Ratio-3.01
Dividend YieldN/A
Beta2.59

About Acer Therapeutics (NASDAQ:ACER)

Acer Therapeutics logoAcer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).

Receive ACER News and Ratings via Email

Sign-up to receive the latest news and ratings for ACER and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100

Debt

Debt-to-Equity RatioN/A
Current Ratio4.11%
Quick Ratio4.11%

Price-To-Earnings

Trailing P/E Ratio-3.00605908784895
Forward P/E Ratio-11.68
P/E GrowthN/A

Sales & Book Value

Annual Sales$2.90 million
Price / Sales43.92
Cash FlowN/A
Price / CashN/A
Book Value$3.91 per share
Price / Book4.42

Profitability

Trailing EPS($5.75)
Net Income$-7,970,000.00
Net MarginsN/A
Return on Equity-108.02%
Return on Assets-88.85%

Miscellaneous

Employees36
Outstanding Shares7,370,000

Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions

What is Acer Therapeutics' stock symbol?

Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."

How were Acer Therapeutics' earnings last quarter?

Acer Therapeutics Inc (NASDAQ:ACER) announced its quarterly earnings results on Monday, November, 13th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter. View Acer Therapeutics' Earnings History.

Where is Acer Therapeutics' stock going? Where will Acer Therapeutics' stock price be in 2018?

2 Wall Street analysts have issued 12-month price objectives for Acer Therapeutics' shares. Their predictions range from $50.00 to $50.00. On average, they anticipate Acer Therapeutics' stock price to reach $50.00 in the next twelve months. View Analyst Ratings for Acer Therapeutics.

Who are some of Acer Therapeutics' key competitors?

Who are Acer Therapeutics' key executives?

Acer Therapeutics' management team includes the folowing people:

  • Christopher Schelling, President, Chief Executive Officer, Director (Age 41)
  • Harry S. Palmin, Chief Financial Officer (Age 47)
  • Jason Kneeland, Vice President - Finance, Controller
  • Terrie Kellmeyer Ph.D., Vice President - Clinical Science
  • John S. Klopp, Vice President - Manufacturing
  • Kim Tharaldsen, Senior Director of Marketing
  • William T. Andrews, Chief Medical Officer (Age 51)
  • Jason Amello, Director
  • Stephen J. Aselage, Director
  • Hubert Birner, Director

Who owns Acer Therapeutics stock?

Acer Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (2.04%), J. Goldman & Co LP (1.47%), Stonepine Capital Management LLC (1.36%) and Ardsley Advisory Partners (0.21%). Company insiders that own Acer Therapeutics stock include Steve Aselage and Timothy C Barabe. View Institutional Ownership Trends for Acer Therapeutics.

Who bought Acer Therapeutics stock? Who is buying Acer Therapeutics stock?

Acer Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, J. Goldman & Co LP, Stonepine Capital Management LLC and Ardsley Advisory Partners. View Insider Buying and Selling for Acer Therapeutics.

How do I buy Acer Therapeutics stock?

Shares of Acer Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acer Therapeutics' stock price today?

One share of Acer Therapeutics stock can currently be purchased for approximately $17.28.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $133.77 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-7,970,000.00 in net income (profit) each year or ($5.75) on an earnings per share basis. Acer Therapeutics employs 36 workers across the globe.

How can I contact Acer Therapeutics?

Acer Therapeutics' mailing address is 222 THIRD STREET SUITE 2240, CAMBRIDGE MA, 02142. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]


MarketBeat Community Rating for Acer Therapeutics (ACER)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acer Therapeutics (NASDAQ:ACER) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyN/AHold
Consensus Rating Score: 3.003.00N/A2.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $50.00$50.00N/A$18.00
Price Target Upside: 195.68% upside216.26% upsideN/A429.41% upside

Acer Therapeutics (NASDAQ:ACER) Consensus Price Target History

Price Target History for Acer Therapeutics (NASDAQ:ACER)

Acer Therapeutics (NASDAQ:ACER) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018William BlairInitiated CoverageOutperformHighView Rating Details
1/4/2018HC WainwrightSet Price TargetBuy$50.00HighView Rating Details
10/28/2016Maxim GroupDowngradeBuy -> HoldN/AView Rating Details
10/28/2016Chardan CapitalDowngradeBuy -> NeutralN/AView Rating Details
10/28/2016AegisDowngradeBuy -> HoldN/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Acer Therapeutics (NASDAQ:ACER) Earnings History and Estimates Chart

Earnings by Quarter for Acer Therapeutics (NASDAQ:ACER)

Acer Therapeutics (NASDAQ ACER) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($1.09)ViewN/AView Earnings Details
8/14/2017Q2 2017($0.93)ViewN/AView Earnings Details
5/12/2017Q1 2017($0.12)ViewN/AView Earnings Details
3/28/2017Q4 2016($1.04)$0.73 millionViewN/AView Earnings Details
11/14/2016Q3 2016($0.25)($0.28)$0.73 millionViewN/AView Earnings Details
8/11/2016Q216($0.23)($0.30)$0.73 million$0.73 millionViewListenView Earnings Details
5/12/2016Q116($0.35)($0.31)$0.73 million$0.73 millionViewListenView Earnings Details
3/15/2016Q415($0.50)($2.05)$0.73 million$0.73 millionViewListenView Earnings Details
11/10/2015Q315($2.48)($0.42)$0.73 million$0.73 millionViewN/AView Earnings Details
8/12/2015Q215($0.08)($0.07)$0.73 millionViewListenView Earnings Details
5/12/2015Q1($0.15)($0.12)$0.38 millionViewListenView Earnings Details
2/23/2015Q4 2014($9.94)$0.31 millionViewN/AView Earnings Details
11/6/2014($0.14)($0.12)$0.30 million$0.31 millionViewN/AView Earnings Details
8/14/2014Q214($0.13)($0.15)$0.30 million$0.31 millionViewN/AView Earnings Details
5/14/2014Q114($0.13)($0.13)$0.22 million$0.35 millionViewN/AView Earnings Details
11/7/2013Q3 2013($32.30)$0.35 millionViewN/AView Earnings Details
8/14/2013Q213($0.37)$0.35 millionViewN/AView Earnings Details
5/14/2013Q1 2013($48.03)$0.22 millionViewN/AView Earnings Details
11/14/2012Q312($0.10)ViewN/AView Earnings Details
8/13/2012Q2 2012($31.14)ViewN/AView Earnings Details
5/11/2012Q1 2012($34.12)ViewN/AView Earnings Details
2/27/2012Q4 2011($26.50)ViewN/AView Earnings Details
11/4/2011Q3 2011($18.55)ViewN/AView Earnings Details
8/11/2011Q2 2011($21.20)ViewN/AView Earnings Details
5/6/2011Q1 2011($20.54)ViewN/AView Earnings Details
3/8/2011Q4 2010($16.56)ViewN/AView Earnings Details
11/9/2010Q3 2010($23.19)ViewN/AView Earnings Details
8/6/2010Q2 2010($26.50)($38.10)ViewN/AView Earnings Details
5/13/2010Q1 2010($26.50)($30.48)ViewN/AView Earnings Details
3/5/2010Q4 2009($29.81)ViewN/AView Earnings Details
11/4/2009Q3 2009$7.29ViewN/AView Earnings Details
8/13/2009Q2 2009($2,030.97)ViewN/AView Earnings Details
5/15/2009Q1 2009($44.39)ViewN/AView Earnings Details
4/16/2009Q4 2008($43.06)ViewN/AView Earnings Details
10/23/2008Q3 2008($102.69)($91.10)ViewN/AView Earnings Details
8/14/2008Q2 2008($125.88)($117.93)ViewN/AView Earnings Details
5/13/2008Q1 2008($162.32)($123.56)ViewN/AView Earnings Details
3/18/2008Q4 2007($188.82)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Acer Therapeutics (NASDAQ:ACER) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.48 EPS
Next Year EPS Consensus Estimate: $-3.06 EPS

Dividends

Dividend History for Acer Therapeutics (NASDAQ:ACER)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Acer Therapeutics (NASDAQ ACER) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.88%
Institutional Ownership Percentage: 1.52%
Insider Trades by Quarter for Acer Therapeutics (NASDAQ:ACER)

Acer Therapeutics (NASDAQ ACER) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017Steve AselageDirectorBuy2,000$12.00$24,000.00View SEC Filing  
11/18/2016Timothy C BarabeDirectorSell14,914$0.55$8,202.7020,719View SEC Filing  
9/17/2014Timothy C BarabeDirectorBuy10,000$1.15$11,500.00View SEC Filing  
9/16/2014Neil K WarmaCEOBuy10,000$1.11$11,100.00View SEC Filing  
12/18/2013Karthik RadhakrishnanCFOBuy8,000$1.70$13,600.00View SEC Filing  
12/18/2013Scott B SeamanDirectorBuy30,000$1.70$51,000.00View SEC Filing  
8/8/2013Karthik RadhakrishnanCFOBuy50,000$1.50$75,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Acer Therapeutics (NASDAQ ACER) News Headlines

Source:
DateHeadline
 Acer Therapeutics Inc (ACER) Given $50.00 Average Target Price by Analysts Acer Therapeutics Inc (ACER) Given $50.00 Average Target Price by Analysts
www.americanbankingnews.com - February 20 at 5:32 PM
Acer Therapeutics (ACER) Earns Outperform Rating from Analysts at William BlairAcer Therapeutics (ACER) Earns Outperform Rating from Analysts at William Blair
www.americanbankingnews.com - February 16 at 10:28 PM
Zacks: Brokerages Expect Acer Therapeutics Inc (ACER) Will Announce Earnings of -$0.62 Per ShareZacks: Brokerages Expect Acer Therapeutics Inc (ACER) Will Announce Earnings of -$0.62 Per Share
www.americanbankingnews.com - February 10 at 7:24 AM
Global Orphan Drugs IndustryGlobal Orphan Drugs Industry
www.bizjournals.com - February 6 at 4:12 PM
Acer Therapeutics Expands Management Team with the Appointment of Three Executives and One New Key HireAcer Therapeutics Expands Management Team with the Appointment of Three Executives and One New Key Hire
finance.yahoo.com - February 5 at 9:22 AM
Acer Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare ConferenceAcer Therapeutics to Present at the LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - January 31 at 9:48 AM
Critical Comparison: Acer Therapeutics (ACER) and Cytokinetics (CYTK)Critical Comparison: Acer Therapeutics (ACER) and Cytokinetics (CYTK)
www.americanbankingnews.com - January 30 at 7:56 AM
Zacks: Brokerages Anticipate Acer Therapeutics Inc (ACER) Will Post Earnings of -$0.62 Per ShareZacks: Brokerages Anticipate Acer Therapeutics Inc (ACER) Will Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - January 24 at 9:12 AM
Zacks: Opexa Therapeutics, Inc. (ACER) Given Average Recommendation of "Buy" by BrokeragesZacks: Opexa Therapeutics, Inc. (ACER) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - January 9 at 5:10 AM
Opexa Therapeutics, Inc. (ACER) Expected to Post Earnings of -$0.62 Per ShareOpexa Therapeutics, Inc. (ACER) Expected to Post Earnings of -$0.62 Per Share
www.americanbankingnews.com - January 7 at 3:08 AM
Acer Therapeutics to Present at the Biotech Showcase™ 2018 ConferenceAcer Therapeutics to Present at the Biotech Showcase™ 2018 Conference
finance.yahoo.com - January 3 at 6:00 PM
Reviewing Opexa Therapeutics (ACER) & TRACON Pharmaceuticals (TCON)Reviewing Opexa Therapeutics (ACER) & TRACON Pharmaceuticals (TCON)
www.americanbankingnews.com - December 31 at 7:30 AM
Opexa Therapeutics (ACER) Rating Lowered to Sell at ValuEngineOpexa Therapeutics (ACER) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - December 30 at 11:18 AM
Acer Therapeutics Announces Partial Exercise of Over-allotment Option in Public OfferingAcer Therapeutics Announces Partial Exercise of Over-allotment Option in Public Offering
finance.yahoo.com - December 28 at 5:18 PM
Opexa Therapeutics (ACER) Now Covered by Analysts at HC WainwrightOpexa Therapeutics (ACER) Now Covered by Analysts at HC Wainwright
www.americanbankingnews.com - December 20 at 8:06 PM
Opexa Therapeutics, Inc. (ACER) Director Acquires $24,000.00 in StockOpexa Therapeutics, Inc. (ACER) Director Acquires $24,000.00 in Stock
www.americanbankingnews.com - December 18 at 6:52 PM
Acer Therapeutics Announces Closing of Underwritten Public Offering of Common StockAcer Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
finance.yahoo.com - December 14 at 6:28 PM
Acer Therapeutics Announces Proposed Underwritten Public Offering of Common StockAcer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
finance.yahoo.com - December 11 at 6:11 PM
 Opexa Therapeutics, Inc. (ACER) Receives Average Recommendation of "Hold" from Analysts Opexa Therapeutics, Inc. (ACER) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 10 at 5:18 PM
Opexa Therapeutics (ACER) and The Competition Critical ComparisonOpexa Therapeutics (ACER) and The Competition Critical Comparison
www.americanbankingnews.com - December 7 at 1:16 PM
Reviewing Opexa Therapeutics (ACER) and Its RivalsReviewing Opexa Therapeutics (ACER) and Its Rivals
www.americanbankingnews.com - November 29 at 3:20 PM
Zacks: Opexa Therapeutics, Inc. (ACER) Receives Average Rating of "Hold" from AnalystsZacks: Opexa Therapeutics, Inc. (ACER) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - November 18 at 3:37 AM
Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release)
globenewswire.com - November 14 at 3:54 PM
Acer Therapeutics Inc. (ACER) Releases Quarterly  Earnings ResultsAcer Therapeutics Inc. (ACER) Releases Quarterly Earnings Results
www.americanbankingnews.com - November 14 at 8:20 AM
Acer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateAcer Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 13 at 6:05 PM
Comparing Opexa Therapeutics (ACER) and Its CompetitorsComparing Opexa Therapeutics (ACER) and Its Competitors
www.americanbankingnews.com - November 9 at 1:12 AM
Comparing Redhill Biopharma (RDHL) & Opexa Therapeutics (ACER)Comparing Redhill Biopharma (RDHL) & Opexa Therapeutics (ACER)
www.americanbankingnews.com - October 23 at 10:58 AM
Reviewing Opexa Therapeutics (ACER) and La Jolla Pharmaceutical (LJPC)Reviewing Opexa Therapeutics (ACER) and La Jolla Pharmaceutical (LJPC)
www.americanbankingnews.com - October 21 at 6:38 AM
Acer Therapeutics (ACER) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowAcer Therapeutics (ACER) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - October 18 at 3:40 PM
Acer Therapeutics Appoints Dr. William T. Andrews as Chief Medical OfficerAcer Therapeutics Appoints Dr. William T. Andrews as Chief Medical Officer
finance.yahoo.com - October 5 at 12:35 PM
 Opexa Therapeutics, Inc. (ACER) Receives Average Recommendation of "Hold" from Brokerages Opexa Therapeutics, Inc. (ACER) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 1 at 10:44 AM
Acer Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferenceAcer Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 22 at 12:13 PM

SEC Filings

Acer Therapeutics (NASDAQ:ACER) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Acer Therapeutics (NASDAQ:ACER) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Acer Therapeutics (NASDAQ ACER) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.